Vaishali Pharma Ltd

Vaishali Pharma has experienced fluctuating financial performance, with net sales increasing from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, but significant declines in profitability and negative cash flow in March 2025. Despite growth in total assets and a reduction in debt, the company's operating profit margin and profits before and after tax have sharply decreased.

Vaishali Pharma has experienced significant fluctuations in financial performance, with net sales increasing from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, but profitability metrics like operating profit margin and profit after tax have sharply declined, culminating in negative cash flow of -INR 18 crore in March 2025. Overall, the company faces challenges in profitability and cash flow management.

As of 07-Nov, Vaishali Pharma Ltd's stock price is at 9.74, down 1.02%, and has significantly underperformed its sector and the benchmark Sensex. The stock has declined 44.31% year-to-date, despite a recent increase in delivery volume, indicating ongoing challenges in the market.

As of 15-Oct, Vaishali Pharma Ltd's stock price is Rs. 10.40, down 3.26%, and has reached a 52-week low. The company shows weak fundamentals with significant declines in performance and investor interest, making it a risky investment.

As of 30-Sep, Vaishali Pharma Ltd's stock price is at 11.31, down 1.65%, and has significantly underperformed its sector and the broader market, with a year-to-date decline of 35.33% and weak long-term fundamentals. The company's poor financial health and reduced investor participation further exacerbate its challenges.

As of 24-Sep, Vaishali Pharma Ltd's stock price is at 11.99, showing a slight increase but a significant year-to-date drop of 31.45%. The stock is underperforming with declining investor participation and weak fundamentals, indicating a bearish trend and cautious investor sentiment.

As of 23-Sep, Vaishali Pharma Ltd's stock price is at 11.97, down 1.16%, and significantly underperforming its sector. The stock shows a bearish trend with a substantial year-to-date decline of 31.56% and weak fundamentals, leading to decreased investor interest.

As of 22-Sep, Vaishali Pharma Ltd's stock price is flat at 12.11, with mixed recent performance and a significant decline in investor participation. Despite outperforming its sector recently, the stock has underperformed the benchmark Sensex over the long term, indicating a concerning outlook due to weak fundamentals and profitability.

As of 19-Sep, Vaishali Pharma Ltd's stock price is declining at 12.11, with a year-to-date drop of -30.76% and weak long-term fundamentals, including a -145.73% CAGR in operating profits over five years. The stock has underperformed its sector and the broader market, indicating significant challenges and low investor interest.

As of 17-Sep, Vaishali Pharma Ltd's stock price is at 12.06, showing a slight increase but reflecting significant challenges, including a 39.40% decline over the past year and poor financial fundamentals. Despite a recent uptick in investor participation, the company's operational difficulties and inability to service debt raise concerns about its long-term outlook.

As of 16-Sep, Vaishali Pharma Ltd is priced at 12.04, showing a slight increase but trading below all key moving averages, indicating a downward trend. The stock has significant declines in performance and weak fundamentals, raising concerns about its long-term viability.

As of 15-Sep, Vaishali Pharma Ltd's stock price is at 12.03, with a slight increase today but a negative trend over the past week and month. The stock is underperforming compared to the Sensex, with weak long-term fundamentals and declining investor participation, indicating a challenging financial environment.

As of 12-Sep, Vaishali Pharma Ltd's stock price is at 11.96, down 0.83%, and has significantly underperformed its sector and the BSE500 index. The company faces weak fundamentals, including a -145.73% CAGR in operating profits over five years and a negative EBITDA, contributing to a 42.15% decline in stock value over the past year.

As of 11-Sep, Vaishali Pharma Ltd's stock price is at 12.06, showing a slight increase but underperforming against its sector and moving averages. The company faces significant financial challenges, including declining investor interest and weak long-term fundamentals, contributing to its poor performance compared to the broader market.

As of 10-Sep, Vaishali Pharma Ltd's stock price is at 12.05, down 0.99%, and has significantly underperformed its sector and the broader market, with a year-to-date decline of 31.10% and negative long-term fundamentals, resulting in a strong sell classification.

As of 09-Sep, Vaishali Pharma Ltd's stock price is at 12.17, down 1.46%, and has significantly underperformed its sector and the Sensex. The company shows weak financial health with negative growth in operating profits and low profitability metrics, contributing to a year-to-date decline of 30.42%.

As of 05-Sep, Vaishali Pharma Ltd's stock price is at 11.91, down 1.98%, and has significantly underperformed its sector. The company faces serious financial challenges, including negative growth in operating profits and a concerning decline in investor participation, indicating it is a strong sell.

As of 04-Sep, Vaishali Pharma Ltd's stock price is at 12.15, down 0.08%. The stock is in a bearish trend with significant declines in investor participation and poor financial fundamentals, underperforming both in the short and long term compared to the broader market.

As of 03-Sep, Vaishali Pharma Ltd's stock price is at 12.16, down 0.25%. The stock has underperformed recently, with a significant decline in investor participation and a concerning long-term outlook, reflected in negative growth in operating profits and weak profitability metrics.